Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)

被引：0
|
作者：
Gordon, Michael S.
Kluger, Harriet M.
Shapiro, Geoffrey
Kurzrock, Razelle
Edelman, Gerald
Samuel, Thomas A.
Moussa, Ali H.
Ramies, David A.
Laird, A. Douglas
Schimmoller, Frauke
Shen, Xiaodong
Daud, Adil
机构：
[1] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Texas Oncol, Irving, TX USA
[6] Georgia Hlth Sci Univ, Augusta, GA USA
[7] Canc Care Associates, Tulsa, OK USA
[8] Exelixis, San Francisco, CA USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8531
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
    Smith, David C.
    Smith, Matthew R.
    Sweeney, Christopher
    Elfiky, Aymen A.
    Logothetis, Christopher
    Corn, Paul G.
    Vogelzang, Nicholas J.
    Small, Eric J.
    Harzstark, Andrea L.
    Gordon, Michael S.
    Vaishampayan, Ulka N.
    Haas, Naomi B.
    Spira, Alexander I.
    Lara, Primo N., Jr.
    Lin, Chia-Chi
    Srinivas, Sandy
    Sella, Avishay
    Schoeffski, Patrick
    Scheffold, Christian
    Weitzman, Aaron L.
    Hussain, Maha
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 412 - 419
  • [22] An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors
    Gordon, M. S.
    Edelman, G.
    Galsky, M. D.
    Smith, D. C.
    Schoffski, P.
    Houggy, K.
    Lee, Y.
    Schimmoller, F.
    Shen, X.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with dear cell renal cell carcinoma (METEOR)
    Choueiri, Toni K.
    Escudier, Bernard J.
    Les, Thomas Pow
    Cella, David
    Ru, Qinhua C.
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Heather A. Wakelee
    Scott Gettinger
    Jeffrey Engelman
    Pasi A. Jänne
    Howard West
    Deepa S. Subramaniam
    Joseph Leach
    Michael Wax
    Yifah Yaron
    Dale R. Miles
    Primo N. Lara
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 923 - 932
  • [25] A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer
    Choudhury, Atish D.
    Gray, Kathryn P.
    Supko, Jeffrey G.
    Harshman, Lauren C.
    Taplin, Mary-Ellen
    Pace, Amanda F.
    Farina, Matthew
    Zukotynski, Katherine A.
    Bernard, Brandon
    Kantoff, Philip W.
    Pomerantz, Mark
    Sweeney, Christopher
    PROSTATE, 2018, 78 (14): : 1053 - 1062
  • [26] Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
    Tolaney, Sara M.
    Nechushtan, Hovav
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Chris A.
    Laird, A. Douglas
    O'Keeffe, Bridget
    Shapiro, Geoffrey I.
    Winer, Eric P.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (02) : 305 - 312
  • [27] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Cella, D.
    Lee, Y.
    Laird, D. A.
    Scheffold, C.
    Motzer, R. J.
    BJU INTERNATIONAL, 2013, 112 : 4 - 4
  • [28] Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
    Sara M. Tolaney
    Hovav Nechushtan
    Ilan-Gil Ron
    Patrick Schöffski
    Ahmad Awada
    Chris A. Yasenchak
    A. Douglas Laird
    Bridget O’Keeffe
    Geoffrey I. Shapiro
    Eric P. Winer
    Breast Cancer Research and Treatment, 2016, 160 : 305 - 312
  • [29] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Wakelee, Heather A.
    Gettinger, Scott
    Engelman, Jeffrey
    Janne, Pasi A.
    West, Howard
    Subramaniam, Deepa S.
    Leach, Joseph
    Wax, Michael
    Yaron, Yifah
    Miles, Dale R.
    Lara, Primo N., Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 923 - 932
  • [30] Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)
    Hutson, T. E.
    Davis, I. D.
    Machiels, J. P.
    de Souza, P. L.
    Hong, B. F.
    Rottey, S.
    Baker, K. L.
    Crofts, T.
    Pandite, L.
    Figlin, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345